Please login to the form below

Not currently logged in
Email:
Password:

Positive results from Gardasil efficacy

Gardasil has been shown to hold an efficacy rate of 96 per cent when used to vaccinate against early cervical lesions, according to recent clinical trail results.

Gardasil has been shown to hold an efficacy rate of 96 per cent when used to vaccinate against early cervical lesions, according to recent clinical trail results.

Sanofi Pasteur MD announced results from recent clinical studies of HPV quadrivalent vaccine Gardasil on March 7.

Due to high efficacy rates across the three phase II/III trails, the independent Data and Safety Monitoring Board (DSMB) recommended the studies be stopped so female patients in the placebo group could be given the vaccine.

Professor Charles Lacey, lead investigator from the University of York's Hull York Medical School, said: "The new data confirm the benefit that quadrivalent vaccination can provide in addition to cervical cancer prevention both for women's health and for health authorities.

"Gardasil offers a wide spectrum of protection against genital diseases caused by HPV and both an early and sustained protection which translates into rapid individual and long-lasting socio-economic benefit."

Gardasil also has efficacy rates of 99 per cent when protecting against genital warts and 100 per cent against early and precancerous vulvar and vaginal lesions.

The new data pertaining to the clinical studies conducted by Lacey's research team was presented at the 20th European Congress of Obstetrics and Gynaecology in Lisbon, Portugal.

Gardasil has already been approved in 93 other countries and launched in 76 of them.

11th March 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics